Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | polymerase (DNA directed) iota | Starlite/ChEMBL | No references |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Mycobacterium tuberculosis | Conserved hypothetical protein | 0.0023 | 1 | 0.5 |
Echinococcus granulosus | dna polymerase eta | 0.0023 | 1 | 0.5 |
Trypanosoma brucei | DNA polymerase IV, putative | 0.0023 | 1 | 1 |
Trypanosoma cruzi | DNA polymerase eta, putative | 0.0023 | 1 | 0.5 |
Brugia malayi | ImpB/MucB/SamB family protein | 0.0023 | 1 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0023 | 1 | 0.5 |
Echinococcus multilocularis | dna polymerase kappa | 0.0023 | 1 | 0.5 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 1 | 1 |
Trichomonas vaginalis | DNA polymerase eta, putative | 0.0023 | 1 | 0.5 |
Trypanosoma brucei | DNA polymerase IV, putative | 0.0023 | 1 | 1 |
Echinococcus multilocularis | dna polymerase eta | 0.0023 | 1 | 0.5 |
Mycobacterium tuberculosis | Possible DNA-damage-inducible protein P DinP (DNA polymerase V) (pol IV 2) (DNA nucleotidyltransferase (DNA-directed)) | 0.0023 | 1 | 0.5 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 1 | 1 |
Echinococcus granulosus | dna polymerase kappa | 0.0023 | 1 | 0.5 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 1 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 1 | 1 |
Trypanosoma cruzi | DNA polymerase kappa, putative | 0.0023 | 1 | 0.5 |
Trypanosoma cruzi | DNA polymerase kappa, putative | 0.0023 | 1 | 0.5 |
Giardia lamblia | DINP protein human, muc B family | 0.0023 | 1 | 0.5 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 1 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 1 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 1 | 1 |
Loa Loa (eye worm) | ImpB/MucB/SamB family protein | 0.0023 | 1 | 0.5 |
Trichomonas vaginalis | DNA polymerase IV / kappa, putative | 0.0023 | 1 | 0.5 |
Trypanosoma brucei | DNA polymerase IV, putative | 0.0023 | 1 | 1 |
Echinococcus granulosus | terminal deoxycytidyl transferase rev1 | 0.0023 | 1 | 0.5 |
Leishmania major | DNA polymerase kappa, putative | 0.0023 | 1 | 0.5 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 1 | 1 |
Mycobacterium ulcerans | DNA polymerase IV | 0.0023 | 1 | 0.5 |
Schistosoma mansoni | DNA polymerase eta | 0.0023 | 1 | 0.5 |
Leishmania major | DNA polymerase kappa, putative,DNA polymerase IV, putative | 0.0023 | 1 | 0.5 |
Trypanosoma cruzi | DNA polymerase kappa, putative | 0.0023 | 1 | 0.5 |
Mycobacterium ulcerans | DNA polymerase IV | 0.0023 | 1 | 0.5 |
Trypanosoma brucei | DNA polymerase eta, putative | 0.0023 | 1 | 1 |
Trypanosoma brucei | unspecified product | 0.0023 | 1 | 1 |
Schistosoma mansoni | terminal deoxycytidyl transferase | 0.0023 | 1 | 0.5 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 1 | 1 |
Schistosoma mansoni | rab geranylgeranyl transferase alpha subunit | 0.0023 | 1 | 0.5 |
Leishmania major | DNA polymerase eta, putative | 0.0023 | 1 | 0.5 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 1 | 1 |
Echinococcus multilocularis | terminal deoxycytidyl transferase rev1 | 0.0023 | 1 | 0.5 |
Entamoeba histolytica | deoxycytidyl transferase, putative | 0.0023 | 1 | 0.5 |
Trypanosoma cruzi | DNA polymerase kappa, putative | 0.0023 | 1 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 10 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Potency (functional) | = 31.6228 um | PUBCHEM_BIOASSAY: qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature. (Class of assay: confirmatory) | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.